ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Study Protocol

Rationale and design of perioperative myocardial ischemia: a protocol for troponin monitoring, prognostic thresholds, economic analysis and further insights into pathophysiology for non-cardiac surgery patients

[version 1; peer review: 1 approved, 1 approved with reservations]
PUBLISHED 12 Jun 2019
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Introduction: Worldwide, near 200 million adults undergo major non cardiac surgery   each year, and 10 million of them are estimated to suffer a myocardial injury after non-cardiac surgery (MINS), defined as an elevated high sensitive troponin T (hs-cTnT) in the first 3 days after surgery. Troponin levels need to be monitored in order to diagnose MINS, high sensitive cardiac Troponin T (hs-cTnT) assays being currently the most frequently used. Perioperative hs-cTnT screening could lead to care decisions that can potentially improve clinical outcomes. However, many of the clinical and economic implications of perioperative hs-cTnT monitoring remain unclear, and need to be elucidated.
Methods and analysis: Prospective cohort that will include patients with high cardiovascular risk undergoing major non-cardiac surgery, expected to require at least an overnight hospital admission. Three determinations of hs-cTnT in each patient (before surgery, at 48, and 72 hours after surgery) will be obtained. We will determine the incidence and prognosis of MINS, and calculate prognostically relevant thresholds for pre- and post-operative hs-cTnT. We will also conduct a cost-effectiveness analysis of hs-cTnT screening, compared with usual care. Finally, using computed tomography angiography (CTA) and cardiac magnetic resonance imaging (MRI), we aim to elucidate further the pathophysiology of MINS.
Ethics and dissemination: Our center had Ethics approval before including patients. Written informed consent is required for all patients before inclusion. The study  will evaluate the feasibility and impact of implementing an hs-cTnT monitoring program at a tertiary hospital, as well as its cost-effectiveness, determine pre and postoperative thresholds of hs-cTnT and finally, evaluate potential mechanisms involved in perioperative ischemic events. The dissemination plan includes publishing the results in a policy-influencing journal, conference presentations, engagement of influential medical organizations, and taking published results to real practice.

Keywords

Myocardial Ischemia, PMI, MINS, hs-cTnT, cost-effectiveness, CT-angiography, MRI.

Strengths and limitations of this study

  • Our study will evaluate the feasibility and impact of implementing a high sensitive cardiac Troponin T (hs-cTnT) monitoring program in patients undergoing non-cardiac surgery, and will inform preoperative and post-operative prognostically relevant thresholds.

  • The study will also determine the cost-effectiveness of hs-cTnT monitoring compared with usual care.

  • Our cardiac imaging sub-study is the first case-control cohort application of non-invasive advance imaging diagnostic tools, computed tomography angiography (CTA), and cardiac magnetic resonance imaging (MRI) with the objective to better understand the pathophysiology of myocardial injury after non-cardiac surgery (MINS).

  • During the implementation of hs-cTnT monitoring, some troponin measurements and, in consequence, some of MINS events may be missed in patients who do not experience ischemic symptoms.

  • Due to the case-control design of the cardiac imaging sub-study, there might be difficulties to include healthy controls, as they might be reluctant to undergo further diagnostic testing.

Introduction

Surgery and cardiovascular complications

Worldwide, annually over 200 million adults undergo major non-cardiac surgery1 and this number is growing continuously. Despite preoperative screening, technical improvement and early detection during clinical screening, perioperative myocardial injury (PMI) remains the first cause of morbidity and mortality within 30 days of surgery2. Available evidence indicates that patients undergoing non-cardiac surgery with only elevated cardiac markers reflecting cardiac injury, such as troponin, have a very poor prognosis3. However, most of these patients do not experience ischemic symptoms, and do not fulfill criteria for conventional clinical diagnosis of myocardial infarction (MI).

The clinical profile and short-term prognosis of patients undergoing non-cardiac surgery, was described in one of the largest multicentre international cohorts (VISION study)4, suggesting a new entity called myocardial injury after non-cardiac surgery (MINS)5, defined as troponin T elevation (≥0.03 ng/ml) in the first 3 days post-surgery. The definition of MINS is broader than the definition of MI as it also includes other prognostically relevant PMIs due to ischemia, but does not include PMIs due to non-ischemic causes (e.g. pulmonary embolism, sepsis, or cardioversion)5. Another recent prospective diagnostic study confirmed that despite early detection during routine clinical screening, PMI is associated with substantial short- and long-term mortality6. Therefore MINS, usually undetected by the absence of ischemic symptoms, is the most common major cardiovascular complication after non-cardiac surgery7, with more than 10 million patients potentially suffering these complications annually worldwide47.

Troponin is the only available biomarker which helps to identify and manage MINS patients, providing rapid, specific and sensitive detection47. Routine monitoring for perioperative cardiac biomarkers, with the most frequently used high-sensitive cardiac Troponin T (hs-cTnT) assay, leads to recognize most of MINS and may improve prognosis. Preoperative hs-cTnT concentrations are also associated with postoperative MI and long-term mortality after non-cardiac surgery8. Typically, hs-cTnT monitoring is determined only in the post-operative period4, and despite the fact that some studies have determined hs-cTnT within 30 days before surgery6, a preoperative threshold has not yet been established.

In order to prevent missing this prognostically relevant event, nowadays guidelines recommend monitoring perioperative troponin in high-risk patients undergoing major non-cardiac surgery9,10. However, little is known about the economic consequences of troponin monitoring11, therefore economic evaluations of troponin monitoring compared to usual care, are needed. The implementation of postoperative troponin monitoring seems cost-effectively, particularly in patients at high risk for MINS12.

Finally, despite a lot of recent interest mechanisms underlying MINS remain unclear13. There is laboratory, autopsy, imaging, and clinical evidence suggesting that coronary artery thrombosis may be one of the main pathophysiological mechanisms14,15. Theoretically, myocardial injury may originate from four main distinct mechanisms: coronary plaque rupture13,14, a myocardial oxygen supply-demand mismatch15,16, non-ischemic cardiac disorders such an atrial fibrillation episode17, or a non-cardiac cause as pulmonary embolism18. Minimally invasive diagnostic tools such as computed tomography angiography (CTA), together with cardiac magnetic resonance imaging (MRI), could help understand underlying mechanisms of MINS, and potentially improve the management and prognosis of these patients.

Given the above, we will evaluate the feasibility and impact of the implementation of routine hs-cTnT monitoring for the detection of prognostically relevant myocardial injury, determine hs-cTnT thresholds that could best predict short and long-term prognosis, conduct a full cost-effectiveness analysis, and further elucidate the pathophysiological mechanisms of MINS in high-risk patients undergoing major non-cardiac surgery.

Methods

The study is divided in three sub-studies.

1) Hs-cTnT screening programme implementation and clinical evaluation

Objectives

  • To implement a hs-cTnT monitoring program in high-risk non-cardiac surgical patients

  • To determine the incidence and prognosis of MINS detected by a monitoring program

  • To determine which cut-off points of hs-cTnT better discriminate patients with death and/or MACE (myocardial infarction, unstable angina, congestive heart failure, new atrial fibrillation, stroke or pulmonary embolism) events (at 30 days and at 1 year) from those without.

Design

Prospective cohort.

Study population

We will include adults ≥65 years or <65 years with documented cardiovascular disease (history of coronary artery disease, chronic heart failure, stroke and peripheral vascular disease), undergoing a major non-cardiac surgery (intraperitoneal, intrathoracic, major vascular, major orthopaedic, emergency) and expected to require at least an overnight hospital admission, that meets inclusion criteria, and no exclusion criteria (Table 1).

Table 1. Eligibility criteria.

Inclusion criteria    •   Age ≥65 years
    •   Age <65 years and documented cardiovascular disease*
    •   Renal insufficiency (estimated glomerular filtration rate <60 ml/min/m2)
Exclusion criteria    •   Non cardiac surgery that does not require an overnight hospital admission or that only receives infiltrative (i.e. local) or
topical anaesthesia
    •   Dementia or mental diseases
    •   Decline to participate

*History of coronary artery disease, chronic heart failure, stroke, or peripheral vascular disease.

Patient recruitment

Research personal will screen all surgical patients daily, both scheduled and emergency, to identify eligible patients. Potentially eligible patients will be approached to obtain informed consent after surgery and before hospital discharge. Template informed consent forms to be used are available as Extended data19.

Procedures

We will measure hs-cTnT using a Roche Cobas e601 analyser (limit of detection 5.0 ng/L, 99th percentile 14 ng/L, 10% coefficient of variation at 13 ng/L) at three predefined time points: preoperatively (during the preoperative visit or just before surgery), and at 48 h and 72 h after surgery. If a rise and/or fall of hs-cTnT with at least one value above the 99th percentile upper reference (14 ng/L) is detected, a cardiologist will perform a clinical evaluation for possible MINS related symptoms, and a 12-lead electrocardiogram (ECG). If the post-surgery ECG has no changes, compared with ECG before surgery, we will conduct an echocardiography. In all included patients the cardiologist will conduct a structured clinical evaluation that will include the revision of current relevant medication (ASA and other antiplatelet, ACE inhibitors, statins, beta-blockers, anticoagulants). Cardiologists will discuss all treatment decisions derived from this visit and will discuss with treating surgeons (see Figure 1).

fe5f713e-01f1-40d7-8d1e-e781a9b917dc_figure1.gif

Figure 1. The high-sensitive troponin T (hs-cTnT) monitoring program flow chart.

A Coordination Committee will carry out periodic meetings to develop and assess the optimal implementation of the hs-cTnT monitoring strategy. Throughout the study we will have periodic meetings with, surgeons, anaesthesiologists, cardiologists, internists, and biochemistry personnel to explore barriers and perceptions about the monitoring program implementation. Alternatively, in case of detecting difficulties the Committee will propose potential solutions or alternative strategies. The Committee will include surgeons from the main surgical departments (orthopaedic, vascular, general, thoracic, plastic, otorhinolaryngology, and neurosurgery), anaesthesiologists, internists, and clinical epidemiologists.

To improve compliance with the screening program, we will aim to implement electronic solutions as much as possible, including the adaptation of electronic preoperative requests templates. For post-operative hs-cTnT measurements at 48 h and 72 h after surgery, we will involve corresponding treating surgical departments, and aim to implement automatically alerts on the electronic health records, as well as for cardiologist consultations. While these strategies are implemented, study personal will guarantee the optimal compliance of all circuits during the study period. Gradually the goal is that the monitoring program is run without the need of additional study personal, and that it is embedded within clinical routine.

Follow-up

We will follow-up all recruited patients during hospitalization, at 1 month and at 1 year after the date of surgery. The 1-month and 1-year follow-up visits will be performed by telephone. If the patients (or relatives) indicate that they have experienced any of the main outcomes, we will obtain the relevant source documents (Table 2).

Table 2. Study procedure and follow-up schedule.

Time PeriodBaselineSurgery
assessment
Post-surgery
assessment
Hospital
discharge
1-month
follow-up
1-year
follow-up
Eligibility Assessmentx
Informed Consentx
Demographicsx
Medical Historyx
Vitals signsxxx
Laboratory tests
(haemoglobin, creatinine)
xxxx
Surgery Detailsx
Troponin*xx
Current relevant
medication**
xxxx
Re-surgeryxxx
Re-hospitalizationxx

*High-sensitive cardiac Troponin T before surgery and at 48 and 72 hours after surgery.

**ASA and other antiplatelet, ACE inhibitors, statins, beta-blockers, and anticoagulants.

Sample size

We estimated the sample size considering our experience with previous perioperative studies in our hospital (Hospital de la Santa Creu i Sant Pau) and a pilot study. In the hospital, approximately 80–100 patients per month (up to 1,000 patients per year) undergo major non-cardiac surgery. We therefore expect to recruit approximately 60–65 patients per month and a total of approximately 1,500 patients over a two-year period. From an estimated incidence of death (1–2%)4,7, and of major adverse cardiac events (MACE) (myocardial infarction, unstable angina, congestive heart failure, new atrial fibrillation, stroke or pulmonary embolism) (8–10%), we expect to observe 15–30 deaths and approximately 120–150 MACE composite events. We also expect to observe a 10% incidence of MINS (150 cases). This sample size will allow as estimating incidence of MINS, death and MACE events with a precision greater than 1.5% for the corresponding 95% confidence intervals.

Data collection methods and data management

We will obtain all data about hospital management (baseline, operative, and hospital discharge), and after discharge at one month and one year. We will collect the number of hs-cTnT measurements ordered by clinicians. We will also register the number of performed structured cardiologist visits. We will register occurrence of MINS, MACE, death and changes of medication during hospitalization, at 1 month and 1 year after surgery. Study personnel will collect data on case report forms (CRFs) and enter this information in a secure computerized database. Patients will be identified using a unique numeric code, and all patient data will be anonymized to ensure confidentiality. We will conduct periodically (every quarter) data validity checks ensuring data quality.

Variables

Our main dependent variables will be screening coverage, and the incidence of MINS, death and MACE (myocardial infarction, unstable angina, congestive heart failure, new atrial fibrillation, stroke or pulmonary embolism). The main independent variables will be: age, sex, type of surgery, troponin measurement, cardiac risk index, history of coronary artery disease cardiac arrest, congestive heart failure, peripheral vascular disease, stroke, transient ischemic attack, chronic renal failure, deep venous thrombosis or pulmonary embolism, diabetes, hypertension, current atrial fibrillation, and chronic obstructive pulmonary disease.

Statistical analysis

We will describe variables according to their nature. We will provide the percentage and the number of cases for categorical variables. For quantitative variables, we will provide the mean and standard deviation. In terms of inferential statistics (relationships between variables), for prevalence and/or incidence we will calculate the corresponding 95% confidence intervals. We will explore univariate associations of independent variables to main outcomes (death and MACE) using chi-square test or Fisher’s exact test, and t-tests or non-parametric tests as needed.

We will conduct multivariate analysis using a binary logistic regression model to explore which factors are associated to MACE. The variables entered into the multivariate model will be those that showed statistically significant association in the univariate approach, and those that are considered as clinically relevant. We will obtain a final risk model following a backward elimination strategy. We will assess goodness of fit using the Hosmer-Lemeshow test, and a coefficient of calibration using C statistic to estimate the area under the ROC curve.

Finally, from receiver-operator characteristic (ROC) curve analysis, we will estimate the best pre and post hs-cTnT cut-off values to predict 30 day and 1 year after surgery mortality and MACE. We will select the cut-off that maximizes Youden's index, and select secondary cut off values to achieve sensitivities of 80, 85, 90, and 95%. All tests will use a 5% (alpha = 0.05) significance level and will be two-tailed. We will use SPSS V 25.0 for all the analysis.

2) Cost-effectiveness analysis

Objective

To evaluate the cost-effectiveness of a hs-cTnT monitoring program for the detection of MINS, compared with current practice (no screening).

Design and procedures

We will develop an economic model considering two alternatives: the application of an hs-cTnT monitoring program for the detection of MINS/MI versus current practice, based on the application of standard treatments in the presence of ischemic symptoms.

Our model will include the elaboration of a decision tree for short-term analysis, with a follow-up of patients at 30 days, and a Markov model for long-term analysis (lifetime). Both analyses will be develop from the perspective of the Spanish National Health System (SNS). In the long-term analysis, both costs and effects will be discounted at an annual rate of 3%, as recommended by the economic evaluation guides, and annual Markov cycles will be used.

Data collection and data management

In terms of items of direct healthcare costs, valued in Euros 2018, we will consider the following:

  • Monitoring costs: hs-cTnT tests costs, health professional’s fees, laboratory technician fees, and administrative costs of implementation of the hs-cTnT monitoring program.

  • Diagnostic tests cost: health professionals (cardiologist, nurse) fees, and consumables materials.

  • Costs of treatment: hospitalizations, outpatient visits, and other hospital costs

  • Follow-up patients cost: administrative costs

Given the perspective of the study, we will not include the non-health care costs and indirect costs. The health effects will be expressed as quality-adjusted life years (QALYs) in the lifetime study, and by avoided events in short-term study. We will obtain patients’ utilities from local data20 and the available research literature, searching in MEDLINE, PubMed, and PMC in our literature search. We will use use the following search terms: perioperative medicine, high-sensitivity Troponin T monitoring, Perioperative Myicardial Ischemia, MINS, Troponin T cut-off point, Troponin T monitoring cost-efectivness, computed tomography angiography (CTA), and cardiac magnetic resonance imaging (MRI).

Statistical analysis

We will estimate the incremental cost-effectiveness ratio (ICER) and we will perform sensitivity analysis of the key parameters. We will conduct a probabilistic sensitivity analysis to develop an acceptability curve in the long-term. We will present the results of the study separately; especially by temporal perspective, patient’s age (eg ≥65 years vs. <65 years) and MINS risk group (e.g. MINS vs. MI).

3) Cardiac imaging

Objective

To clarify the underlying mechanisms involved in MINS and PMI in high cardiovascular risk patients undergoing non-cardiac surgery.

Design

Nested case-control study.

Study population

Patients from sub-study 1 will also be included in this sub-study (see eligibility criteria in Table 1).

Sample size

Local pilot data21 shows an incidence of MINS of 10%, and a prevalence of significant coronary atherosclerosis identified by CTA in asymptomatic cardiovascular high-risk Mediterranean people of 18.9%22. We will need 130 patients with MINS/MI and 130 matched controls (adjusting by sex, age within five years interval, type of surgery and Lee index), accepting an alpha risk of 0.05, a beta risk of 0.2 in a two-sided test, and a loss rate of patients of 10%. We will validate our assumptions for this calculation once half of the sample is recruited.

Procedures

Within the postoperative hospitalization period, we will approach eligible patients with the specific sub-study informed consent for the CTA and MRI exams. We will distinguish two groups of patients: cases and controls (Table 3).

Table 3. Definition of cases and controls for cardiac imaging sub-study.

Cases
MINS/MI group
MINS group: patients with hs-cTnT value higher than 50% of preoperative level, without symptoms, without ECG
changes related to ischemia, neither new wall abnormalities in the postoperative echocardiogram.
MI group: patients with perioperative myocardial infarction according to the current definition
ControlsPatients from hs-cTnT monitoring program without MINS or MI

We will perform CTA after 30 days of hospital discharge at Hospital de Sant Pau (Barcelona). Few days before the CTA, a cardiologist will treat patients with a beta-blocker (atenolol 25–50 mg or ivabradine 5–7.5 mg to achieve a heart rate of approximately ≤60 beats per minute). Expert evaluators (cardiologist or radiologist with level 3 training in interpretation of coronary computed tomography angiography), will read each angiogram using a 17-segment model of the coronary arteries, without knowledge of the clinical data. Each scan will be scored as normal (no evidence of coronary atherosclerosis); non-obstructive coronary artery disease (evidence of at least one coronary artery plaque with a <50% stenosis); obstructive coronary artery disease (at least one coronary artery plaque with a ≥50% stenosis); or extensive obstructive disease (≥50% stenosis in two coronary arteries including the proximal left anterior descending artery, ≥50% stenosis in three coronary arteries, or ≥50% stenosis in the left main coronary artery).

After each CTA, we will conduct a MRI exam for every patient to analyse the global and segmental cardiac contractility, an assessment of necrosis and myocardial viability by studying late gadolinium enhancement contrast, and a pharmacological stress test with adenosine in the cases of CTA with obstructive coronary artery disease. After a matching analyses for the principal confounding factors (age, sex, Lee index, and type of surgery), one control for each case will be selected to complete the same CTA and MRI studies.

With the available findings, after the two tests, complemented with clinical anamnesis and relevant ECG changes, MINS patients will be classified into one of the following categories:

• Plaque rupture

• Supply-demand mismatch

• Non-ischemic cardiac cause

• Non-cardiac cause

Data collection and data management

We will collect all perioperative clinical data. We will include the following variables: demographic (age and gender), therapeutic (previous medical treatment with aspirin, other antiplatelet agents, statins or beta-blockers), related diagnostic tests (sensitivity), risk factors (Lee index and type of surgery), comorbidities, and perioperative data.

Statistical analysis

We will describe variables according to their nature. We will obtain absolute and relative frequencies for categorical variables. We will provide the mean and standard deviation for quantitative variables. We will estimate the prevalence of each one of the proposed aetiologies along with their exact 95% confidence intervals in the MINS sub-cohort, and compare these prevalence to the ones observed in the non-MINS cohort. We will assess if there is an association between aetiology and MINS status using contingency tables of each aetiology in the two groups (MINS and non-MINS), along with chi-square test or Fisher’s exact tests for the evaluation of the statistical association. In case of any clearly distinct covariate disbalance, a multivariate approach will be used. We will assess the agreement between diagnostic findings in the MINS population and control group using Cohen’s kappa coefficient. For the significance level we will use a 5% (alpha = 0.05) bilateral approach. We will use SPSS V 25.0 for all the analysis.

Study organization

The study is coordinated by the Hospital de la Santa Creu i Sant Pau (Barcelona), which is primarily responsible for the organization of the study, development, study database, ensuring data quality, ensuring monitoring, coordination of the sub-studies, and data analyses. This study is part of a research line of perioperative medicine, which explores strategies for diagnosis, prevention, treatment, and risk prediction that promotes better management of patients undergoing surgery. The research team of this study is a multidisciplinary group that combines clinical investigators from epidemiology, anesthesiology, cardiology and biochemical departments, with large experience in the perioperative medicine area. The study structure includes an Adjudication Committee, an Operations Committee, and Steering Committee. The Adjudication Committee composed of clinicians who have expertise in perioperative outcomes, adjudicates all important clinical events. The Steering Committee supervises the whole project, and Operations Committee is in charge of the day to running of the study. Each sub-study has one lead investigator, and the project has one principal investigator (PAC). Given that it is an observational cohort it was considered not necessary to have a monitoring committee.

Ethics and dissemination

The protocol has received approval and consent from the Ethics Committee of Clinical Research Institute of our centre. Research personnel or good clinical practice trained health care professionals will obtain written informed consent for each patient. All data will be stored on a central encrypted, high-security computer system and kept strictly confidential.

In the case-control sub-study that includes CTA and MRI explorations, we will be contracted a specific insurance for controls. In case of patients with MINS, the CTA and MRI tests are clinically justified.

Dissemination policy

The knowledge dissemination plan includes traditional modes of dissemination (i.e., publication in a policy-driving journal, national/international conference presentations), as well as engagement of influential medical organizations. Broader dissemination will be performed by the Biomedical Research Institute Sant Pau (IIB Sant Pau) public website, and Twitter account. Also dissemination will be conducted in the Spanish Association of Anesthesia and Cardiology, as well as in our international network of perioperative medicine

Current status of the trial

Approval and consent was received from the Ethics Committee of Clinical Research Institute of the Hospital de la Santa Creu i Sant Pau, for Protocol version: 1.1. Date: 2016-05-09. The study is currently in progress, having screened 1,900 patients, and recruited a total of 1,200 patients. Patient recruitment was initiated in 2016 and will end in 2019.

Discussion

Executive summary

We will evaluate feasibility and impact of the implementation of routine hs-cTnT monitoring for the detection of prognostically relevant myocardial injury. Our proposal will also aim to determine the hs-cTnT threshold that could best predict short and long-term prognosis. Given the scarce evidence regarding the economic aspects of troponin monitoring our cost-effectiveness analysis will provide new important knowledge in this area. Finally, by the application of the advance imaging techniques (CTA and MRI), this proposal will provide further insights in the identification of the mechanisms of MINS in high-risk patients undergoing major non-cardiac surgery.

Our study in the context of previous research

Troponin monitoring. Available evidence indicates that among patients undergoing noncardiac surgery, MINS is common (8%), one in ten patients suffering MINS will die within 30 days, and majority of these events can be only detected with hs-cTnT screening in the first 72 hours after surgery5. Therefore, failure to monitor troponin measurements after noncardiac surgery will result in missing more than 80% of MINS events4,5. In order to prevent missing of this prognostically relevant event and based on recommendations of some guidelines9,10, we will implement hs-cTnT screening programme within clinical routine. However, little is known about the feasibility and impact of hs-cTnT screening in real practice.

Our study will implement routine hs-cTnT screening program, and evaluate its feasibility and impact at a tertiary hospital. Routine screening for perioperative hs-cTnT will lead to recognize most of MINS, improve clinical outcomes, and can potentially reduce short and long-term mortality after major non-cardiac surgery. Differently to previous studies, in case of elevated hs-cTnT a cardiologist will conduct a structured evaluation. Our hypothesis is that patients with a prognostically relevant hs-cTnT peak will likely improve their 1-month and 1-year prognosis if they receive structured management, treatment, and adequate follow-up. Clinicians will be better informed about how to interpret hs-cTnT values, and policy makers will be better informed to decide (or not) to implement routine troponin monitoring in high cardiovascular risk patients.

Preoperative and postoperative hs-cTnT thresholds. In most of the previous studies hs-cTnT was obtained only after surgery4,5; however, in our study hs-cTnT will also be measured before surgery. This will help to determine the relevant pre and post-operative thresholds. There are only a few studies that have measured hs-cTnT levels before the time of surgery. The cohort study within the VINO trial (n = 608), concluded that hs-cTnT concentrations before surgery were significantly associated with postoperative MI, and long-term mortality after non-cardiac surgery8. We also identified a more recent cohort that measured hs-cTnT before surgery (within 30 days before surgery), where PMI was defined as an absolute increase in hs-cTnT of ≥14 ng/L above preoperative value, or between 2 postoperative values if the preoperative value was missing6. On the other hand, nearly half of adults undergoing non-cardiac surgery exceed the 99th percentile of ≥14ng/ post-surgery23, and mild elevations of hs-cTnT are common in men and elderly non-MI patients24, hence, optimal cut-off levels could differ across populations. We identified a single study showing cut-off values to differentiate acute MI from non-acute MI but in non-surgical elderly patients (>70 years old), being nearly four times the 99th percentile with hs-cTnT (54 ng/L). In contrast, the best cut-off value in younger patients was close to the 99th percentile for hs-cTnT (17 ng/L)25. Given the above, there is a need to determine optimal preoperative and post-operative prognostically relevant hs-cTnT thresholds in high cardiovascular risk patients undergoing major non-cardiac surgery.

Economic consequences. There are only few economic analyses studies evaluating the cost effectiveness of hs-cTnT monitoring, including a broad spectrum of non-cardiac surgical procedures. Despite the lack of conclusive economic evidence troponin monitoring is now recommended in some clinical guidelines9,10.

We identified two studies that analysed the cost-effectiveness of troponin monitoring11,12. The first study, conducted in USA, included patients aged ≥65 years undergoing open abdominal aortic aneurysm (AAA) repair11. The authors concluded that postoperative Troponin I screening after AAA repair was cost-effective, with an incremental cost-effectiveness ratio of 2003 US$12,641 per QALY. The second study was recently conducted by VISION study investigators. This is a model-based cost–consequence analysis which compares the impact of routine troponin T monitoring versus standard care on the incidence of MINS12. The model inputs were based on Canadian patients enrolled in VISION study. The costs associated with a troponin T monitoring program to detect MINS were moderate. The study concluded that implementation of troponin T monitoring seems appealing, particularly in patients at high risk for MINS, based on the estimated incremental cost per health gain. No cost-effectiveness analysis of hs-cTnT monitoring high-risk cardiovascular patients in major non-cardiac surgery patients (in comparison with usual care) is yet available. Our study will address this question in the Spanish setting using data from real clinical practice.

MINS pathophysiology. Understanding the pathophysiology of MINS is crucial to develop potential prophylactic and therapeutic interventions to improve the prognostic of patients undergoing non-cardiac surgery. However, angiographic, histological or imaging studies that provide an overview of the incidence of etiological mechanisms of MINS are currently not available. We identified a single study where CTA was used for screening of coronary artery disease before non-cardiac surgery, improving perioperative risk stratification with clinical tools as the Lee index26. VISION study investigators have published a single prospective cohort study (Coronary CTA VISION) with 955 patients using CTA before non-cardiac surgery, concluding that myocardial infarction occurs across the spectrum of coronary artery disease, suggesting that there could be several pathophysiologic mechanisms involved27.

Given the scarce available data better understanding of the pathophysiology of MINS is much needed. With non-invasive diagnostic tools, such as CTA and MRI our study could improve the understanding of the underlying mechanisms involved in MINS. This new knowledge could inform prophylactic and therapeutic interventions.

Study limitations and strengths. Our study has several limitations. During hs-cTnT monitoring implementation, some monitored troponin measurements may be missed, due to fast hospital discharge, no staff collaboration, haemolysis of the samples, etc. Also there may have missed some structured cardiologist visits, due to fast hospital discharge or coordination problems. Therefore, we may miss MINS events in patients who do not experience ischemic symptoms. Regarding the cost-effectiveness study, there may be variability in sample-associated costs and results. Finally, the cardiac imaging sub-study has a nested case-control design, where inclusion of healthy controls without any clinical justification for carrying out diagnostic tests may be difficult.

Our study has also several strengths. It is a rigorous proposal that will address several very relevant questions simultaneously. It will evaluate the feasibility and impact of implementing hs-cTnT monitoring program at a tertiary hospital, with large sample of adults who underwent noncardiac surgery. All patients will undergo troponin monitoring before and after surgery, using the same troponin assay. The study will also inform preoperative and post-operative prognostically relevant thresholds that likely will improve mortality and major cardiovascular events prediction. Our study will also determine the cost-effectiveness of troponin monitoring, and finally, the application of non-invasive advance imaging diagnostic tools (CTA and MRI), will contribute in the identification of the mechanisms involved in MINS.

Implications for practice and research. The results of our cohort study will offer high-quality evidence to guide practice, and will likely have major implications in the management and prognosis of this public health problem. Success of implementation of the hs-cTnT monitoring program will be good example for its implementation in other sites, in Spain and elsewhere. New knowledge about preoperative and post-operative prognostically relevant thresholds will improve the prediction of mortality, and major cardiovascular events.

Given the low cost of hs-cTnT and poor prognosis of patients with MINS, potential management, treatment and hs-cTnT monitoring is likely to be cost-effective for the national health system. Our economic evaluation study will throw light on the cost effectiveness of troponin monitoring compared to usual care, which will likely improve prognosis and unnecessary costs. Policy makers will be better informed to decide (or not), to implement troponin screening in high cardiovascular risk patients.

The understanding of the pathophysiology of MINS will help to develop new prophylactic and therapeutic measures to improve the prognosis of patients, and reduce unnecessary costs. Moreover, the results of this study can help scientists to shape research initiatives in the future, applying these techniques to detection of myocardial injury. The success of this study will allow bringing research results to daily practice, evaluate their implementation, and facilitate further nested research that will address important questions in the field. This study is potentially an example of knowledge transfer, taking published results to real practice, with the aim to influence patient important outcomes.

Data availability

Underlying data

No underlying data are associated with this article.

Extended data

Open Science Framework: Rationale and design of Perioperative Myocardial Ischemia (PMI): a protocol for troponin monitoring, prognostic thresholds, economic analysis and further insights into pathophysiology for non-cardiac surgery patients. https://doi.org/10.17605/OSF.IO/GBV4U19.

Reporting guidelines

Open Science Framework: SPIRIT checklist for “Rationale and design of perioperative myocardial ischemia: a protocol for troponin monitoring, prognostic thresholds, economic analysis and further insights into pathophysiology for non-cardiac surgery patients”. https://doi.org/10.17605/OSF.IO/GBV4U19.

Comments on this article Comments (1)

Version 1
VERSION 1 PUBLISHED 12 Jun 2019
  • Reader Comment 11 Feb 2020
    Joseph Alpert
    11 Feb 2020
    Reader Comment
    This is a reasonable study with a solidly thought out protocol.  The ms is well written and easy to understand.  The study is important. I would accept it as written.  ... Continue reading
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Popova E, Paniagua Iglesias P, Alvarez Garcia J et al. Rationale and design of perioperative myocardial ischemia: a protocol for troponin monitoring, prognostic thresholds, economic analysis and further insights into pathophysiology for non-cardiac surgery patients [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2019, 8:850 (https://doi.org/10.12688/f1000research.18980.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 12 Jun 2019
Views
10
Cite
Reviewer Report 28 Mar 2022
Sebastiano Gili, Invasive Cardiology Department, Centro Cardiologico Monzino, IRCCS, Milan, Italy 
Approved with Reservations
VIEWS 10
Popova and colleagues present the rationale and design for a prospective study aiming to assess the clinical implications and cost-effectiveness of a structured program for the monitoring of pre- and post-operative troponin values in patients undergoing high-risk surgery. The main ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Gili S. Reviewer Report For: Rationale and design of perioperative myocardial ischemia: a protocol for troponin monitoring, prognostic thresholds, economic analysis and further insights into pathophysiology for non-cardiac surgery patients [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2019, 8:850 (https://doi.org/10.5256/f1000research.20805.r126837)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
26
Cite
Reviewer Report 20 Jun 2019
Christian Puelacher, Department of Cardiology, University Hospital of Basel, University of Basel, Basel, Switzerland;  Department of Internal Medicine, University Hospital of Basel, University of Basel, Basel, Switzerland 
Approved
VIEWS 26
The presented protocol seems very promising to help understand the clinical applicability of perioperative hs-cTnT Screening after non-cardiac surgery in high-risk patients in routine practise. The follow-up data on adherence of medication prescribed for MINS will be very interesting. The concept ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Puelacher C. Reviewer Report For: Rationale and design of perioperative myocardial ischemia: a protocol for troponin monitoring, prognostic thresholds, economic analysis and further insights into pathophysiology for non-cardiac surgery patients [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2019, 8:850 (https://doi.org/10.5256/f1000research.20805.r49799)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 02 Aug 2019
    Ekaterine Popova, Iberoamerican Cochrane Center, Biomedical Research Institute, (IIB Sant Pau),, Barcelona, Spain
    02 Aug 2019
    Author Response
    Dear Dr. Puelacher,

    Thank you very much for substantial revision and useful comments and suggestions. However, at this moment only one peer reviewer report has been received, so we can not ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 02 Aug 2019
    Ekaterine Popova, Iberoamerican Cochrane Center, Biomedical Research Institute, (IIB Sant Pau),, Barcelona, Spain
    02 Aug 2019
    Author Response
    Dear Dr. Puelacher,

    Thank you very much for substantial revision and useful comments and suggestions. However, at this moment only one peer reviewer report has been received, so we can not ... Continue reading

Comments on this article Comments (1)

Version 1
VERSION 1 PUBLISHED 12 Jun 2019
  • Reader Comment 11 Feb 2020
    Joseph Alpert
    11 Feb 2020
    Reader Comment
    This is a reasonable study with a solidly thought out protocol.  The ms is well written and easy to understand.  The study is important. I would accept it as written.  ... Continue reading
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.